PCM
RPRX icon

Parsons Capital Management’s Royalty Pharma RPRX Stock Holding History

Parsons Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,859
Closed -$204K – 419
2022
Q2 		$204K Buy
+4,859
New +$199K 0.02% 395

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Parsons Capital Management's RPRX Position: Q3 2022 in Review

Parsons Capital Management sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 4,859 shares — an estimated $204K sold.

Parsons Capital Management first reported a position in RPRX in Q2 2022 and held it in 1 quarter. The position peaked at $204K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

  • Parsons Capital Management reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
  • Parsons Capital Management sold 4,859 Royalty Pharma shares in Q3 2022, an estimated $204K.
  • Parsons Capital Management first reported a position in Royalty Pharma in Q2 2022 and held it in 1 quarter.
  • Parsons Capital Management's Royalty Pharma position peaked at $204K in Q2 2022.
  • 319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Parsons Capital Management's 13F filing for Q3 2022, filed 26 Oct 2022.